Visit https://www.peervoice.com/AMX860 to view the entire programme with slides. After completing “Acute Psychosis: When to Suspect Acute Hepatic Porphyria”, participants will be able to: Recognise acute hepatic porphyria (AHP) in patients with acute psychosis; Identify patients with psychological symptoms who should be screened for AHP; Describe the importance of a multidisciplinary team approach in the management of patients with AHP.

Visit https://www.peervoice.com/WHZ860 to view the entire programme with slides. After completing “Identifying Bowel Urgency in Patients With Ulcerative Colitis: The Need for Speed”, participants will be able to: Explain how bowel urgency can impact a patient’s quality of life; Apply practical strategies for identifying and assessing patients with ulcerative colitis who are suffering from bowel urgency; Describe the clinical data for emerging therapies that are being assessed on their impact on bowel urgency.

Visit https://www.peervoice.com/NTG860 to view the entire programme with slides. After completing “Transforming the Treatment of Acute Hepatic Porphyria”, participants will be able to: Summarise key findings from a published study evaluating the efficacy and safety of a treatment for acute hepatic porphyria (AHP); Evaluate clinical evidence in terms of safety and efficacy, as well as study design, population, and patient-reported outcomes; Discuss the implications of these data for the management of patients with AHP.

Visit https://www.peervoice.com/DHB860 to view the entire programme with slides. After completing “The First Biologic in IBD: When, Which, and Why?”, participants will be able to: Describe the clinical features and treatment goals of inflammatory bowel disease (IBD); Identify patient and drug characteristics that may influence treatment decision-making for patients with IBD; Formulate individualised treatment plans for patients with IBD who require biologic treatment, considering patient-specific factors.

Visit https://www.peervoice.com/QGY860 to view the entire programme with slides. After completing “Proactive IBD Care: Identifying Patients at Risk of Disease Progression”, participants will be able to: Explain the rationale for assessing risk of progression and individualising therapy for patients with inflammatory bowel disease (IBD); Apply emerging risk assessment strategies to identify patients with IBD at risk of progression; and Design effective treatment plans for patients with IBD according to risk stratification.

Visit https://www.peervoice.com/GWP860 to view the entire programme with slides. After completing “Interpreting the Most Recent Clinical Data With A Real-World Lens: Implications on Hepatocellular Carcinoma Management ”, participants will be able to: Discuss the most recent and relevant clinical data that most impacts the systemic treatment of patients with unresectable hepatocellular carcinoma (HCC); Formulate personalised, evidence-based sequencing strategies, developed through a multidisciplinary approach, that optimise the survival of patients with unresectable HCC; and Apply a balanced approach to maximise patient quality of life over the duration of the treatment plan.

Visit https://www.peervoice.com/HHK860 to view the entire programme with slides. After completing “New Targets in IBD: Focus on IL-23”, participants will be able to: Explain the rationale for targeting IL-23 in inflammatory bowel disease (IBD); Evaluate the relative efficacy and safety of IL-23 inhibitors to date for patients with IBD; and Describe how these agents may fit into future treatment algorithms for IBD.

Are All Biologics the Same? Optimal Treatment Strategies for Patients With Inflammatory Bowel Disease

Transforming the Treatment of Acute Hepatic Porphyria

Early Disease Control in Inflammatory Bowel Disease: Integrating the Latest Evidence for Better Outcomes